(E)-3-(2-phenylimidazo[1,2-a]pyridin-3-yl)prop-2-enoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (E)-3-(2-phenylimidazo[1,2-a]pyridin-3-yl)prop-2-enoic acid
• 化学式: C₁₆H₁₂N₂O₂
• 分子量: 264.28
• InChiKey: RUBYIZKMLSFLLU-MDZDMXLPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Beta-amyloid inhibitors, processes for preparing them, and their use in pharmaceutical compositions
  申请人：——

  公开号：US20020042420A1

  公开（公告）日：2002-04-11

  Compounds of general formula (I) 1 wherein: A is —CH 2 —, —CH 2 —CH 2 —, —CH 2 —CH 2 —CH 2 —, —CH 2 —CH 2 —CH 2 —CH 2 —, —CH 2 —CO—, —CH 2 —CH 2 —CO—, or —CH═CH—CO—; Het is piperidinyl, piperazinyl, or dihydrobenzimidazolonyl; R 1 is hydrogen or halogen; R 2 is hydrogen, C 1 -C 4 -alkyl, CF 3 , or a phenyl group optionally substituted by halogen, C 1 -C 4 -alkyl, or C 1 -C 4 -alkyloxy; and R 3 is hydrogen, C 1 -C 4 -alkyl, HO—C 1 -C 4 -alkyl, or C 2 -C 4 -alkenyl; or a group selected from phenyl, benzyl, and phenylethyl, each optionally substituted by halogen, CF 3 , C 1 -C 4 -alkyl, or C 1 -C 4 -alkyloxy; or a heterocycle selected from among morpholine, piperidine, piperazine, and dihydrobenzimidazolone, the heterocycle either linked directly or via a C 1 -C 4 -alkylene bridge, or an optical isomer, enantiomer, tautomer, free base, or pharmacologically acceptable acid addition salt thereof; methods of making such compounds; pharmaceutical compositions thereof, and their use in treating or preventing diseases in which a therapeutic benefit can be obtained by interfering in the process of the formation of A&bgr; or its release from cells, by inhibiting the A&bgr; activity, such as Alzheimer's disease, Parkinson's disease, and Huntington's Chorea.

  通式（I）的化合物，其中：A是—CH2—、— — —、— — — —、— — — — —、— —CO—、— — —CO—或—CH═CH—CO—；Het是哌啶基、哌嗪基或二氢苯并咪唑基；R1是氢或卤素；R2是氢、C1-C4烷基、CF3或苯基，该苯基可选地被卤素、C1-C4烷基或C1-C4烷氧基取代；R3是氢、C1-C4烷基、HO—C1-C4烷基或C2-C4烯基，或从苯基、苄基和苯乙基中选择一种，每种可选地被卤素、 、C1-C4烷基或C1-C4烷氧基取代；或从吗啉、哌啶、哌嗪和二氢苯并咪唑中选择一种杂环，该杂环可以直接连接或通过C1-C4烷基桥连接；或其光学异构体、对映异构体、互变异构体、自由碱基或药理学上可接受的酸加合物盐；制备这种化合物的方法；其制备的药物组成物及其在治疗或预防通过干扰A&bgr;的形成过程或其从细胞释放的过程中获得治疗效果的疾病中的使用，例如阿尔茨海默病、帕金森病和亨廷顿舞蹈病。
• US6514969B2
  申请人：——

  公开号：US6514969B2

  公开（公告）日：2003-02-04